by consultant radiologists as 'unsuitable for EVAR'. 66 had OSR and 52 had Pararenal EVAR (PEVAR).

Results: PEVAR patients were older (74.3yrs vs. 70.8 yrs, p=0.014) with higher mean SVS co-morbidity severity scores (p=0.0001). All procedures were within 14 days of diagnosis. Mean aneurysm diameter was larger in OSR (OSR 6.6cm vs. PEVAR 5.9cm, p=0.010). For PEVAR 83% of endografts were 34mm/36mm. 3-year aneurysm-related survival was significantly higher with PEVAR (100% vs. OSR (92.4%+/−4.37%), p=0.045). PEVAR provided an incremental cost-effectiveness ratio of €129,586 saved per QALY gained. 3-year freedom from secondary intervention (PEVAR 83.4% vs OSR 95.5%, P=0.301) and all-cause survival (PEVAR 57.1% vs OSR 84.8%, p=0.195) were similar. 30-day morbidity halved with PEVAR (15% vs. 30%, p=0.059). Length of hospital stay (p=0.0007) was lower and number of patients fit for discharge to their home (p=0.006) higher with PEVAR.

Conclusions: PEVAR granted our patients longer Q-TWiST and Superior Freedom from MACE up to three years. Despite 3-year survival rate of 57%, PEVAR is cost-effective and offered as Endo-bailing for patients living on borrowed time, abolishes the socio-economic catastrophe of managing a rupture PAAA.

TCT-131

Cerebral Ischemia After Thoracic Endovascular Aortic Repair: A Diffusion-Weighted Magnetic Resonance Imaging Study

Philipp Kahlert[1], Holger Eggebrecht[2], Thomas Konorza[1], Rolf Alexander Janosi[1], Konstantinos Tsagakis[1], Heinz Jakob[1], Raimund Erbel[1], Marc Schlamann[3]
[1]West German Heart Center, Essen, Germany, [2]Cardiovascular Center Bethanien, Frankfurt, Germany, [3]University Hospital Essen, Essen, Germany

Background: The risk of clinical apparent, periprocedural stroke after thoracic endovascular aortic repair (TEVAR) ranges between 2 and 6% and has been associated with increased postoperative mortality. Stroke after TEVAR is thought to be related to multiple emboli, which are dislodged during manipulation of guidewires, catheters and large-bore delivery devices in the diseased aortic arch. Such emboli may also account for clinically silent cerebral ischemia. However, the rate of silent cerebral ischemia in the setting of TEVAR is yet unknown, but may be even higher than the rate of clinical apparent neurological events.

Methods: Twenty patients (12 male, 8 female) who underwent TEVAR were included into this descriptive study; exclusion criteria were a history of stroke, carotid artery disease, renal failure and contraindications for magnetic resonance imaging (MRI). Periprocedural apparent and silent cerebral ischemia was assessed by neurological testing and serial cerebral diffusion-weighted MRI (DW-MRI) at baseline and within the first 10 days (mean: 4.9 days) post procedure.

Results: TEVAR was successful in all patients without immediate clinically apparent neurological deficits. Post-interventional cerebral DW-MRI detected a total of 33 new foci of restricted diffusion in 13 of the 20 patients (65%). Lesions were usually multiple (1-6 lesions per patient) and ranged in size between 15 mm3 and 585 mm3. 17 lesions were found in the left middle cerebral artery and PICA territory, 10 lesions in the right middle cerebral artery and PICA territory. Overstenting of the left-subclavian artery was performed in 9 cases, but was not associated with lateralization of lesions. There were no additional apparent neurological events during the in-hospital period.

Conclusions: TEVAR resulted in a high incidence of new foci of restricted diffusion on cerebral DW-MRI in a pattern suggestive for periprocedural embolization. Although even multiple lesions per patients were found, these lesions were not associated with apparent neurological deficits during the in-hospital period. Further developments in TEVAR should be directed towards reducing the risk of periprocedural cerebral embolization.

TCT-132

Abstract Withdrawn

Chronic Kidney Disease and Acute Renal Insufficiency
Hall D
Tuesday, October, 23, 2012, 8:00 AM–10:00 AM

Abstract nos: 133-150

TCT-133

Role of arterial stiffness and impaired renal function in the progression of non-culprit coronary lesions after percutaneous coronary intervention

Hidehiro Kaneko[1], Junji Yajima[1], Yuji Oikawa[1], Shunsuke Matsuno[1], Shingo Tanaka[1], Daisuke Fukamachi[1], Shinya Suzuki[1], Tadanori Aizawa[1], Takeshi Yamashita[1]
[1]The Cardiovascular Institute, Tokyo, Japan

Background: In the era of drug eluting stent, progression of non-culprit coronary lesion emerged as a new therapeutic target of coronary artery disease. We aimed to clarify the prognostic factors for the progression of non-culprit coronary lesion after percutaneous coronary intervention (PCI).

Methods: We retrospectively examined 401 patients who underwent PCI during February 2010 to January 2011 in our institute. Among them, 275 patients were performed follow-up coronary angiography (CAG) 6-12 months after PCI. Patients with target lesion revascularization (n=39) were excluded. Finally, total of 236 patients were included in this study. Progression of non-culprit lesion was defined as clinically driven PCI because of the development of coronary lesion which was not significant at initial PCI but significant at follow-up CAG, and was associated with ischemic symptom and/or abnormal results of functional study.

Results: Thirty three patients (14%) underwent additional clinically driven PCI to treat non-culprit coronary lesions. There was no difference in background clinical characteristics between patient with or without progression of non-culprit lesion PCI. Prevalence of chronic kidney disease (CKD) (61% vs. 31%, p=0.001) and multi-vessel disease (MVD) (55% vs. 35%, p=0.027) were significantly higher and statin use (61% vs. 72%, p=0.187) was tended to be lower in patients with non-culprit lesion PCI than those without. Brachial-ankle pulse wave velocity (baPWV) was significantly higher in patients with non-culprit lesion PCI than those without (1838±371 vs. 1589±313cm/s, p<0.001). High density lipoprotein cholesterol level at follow-up CAG was tended to be lower in patients with non-culprit lesion PCI than those without (54±15 vs. 58±16mg/dL, p=0.147). Multivariate analysis showed that higher baPWV, CKD, MVD, and lower HDL at follow-up CAG were independent determinants for progression of non-culprit coronary lesion.

Conclusions: In conclusion, higher baPWV, CKD, MVD, and lower HDL at follow-up CAG were independent determinants of non-culprit coronary lesion PCI, suggesting important prognostic role of arterial stiffness and impaired renal function in the progression of non-culprit coronary artery lesion.

TCT-134

Abstract Withdrawn

TCT-135

Contrast Use And Acute Kidney Injury In Contemporary Clinical Practice

Robert Applegate[1], Matthew Sacrinty[1], Jordan Allem[1], Sanjay Gandhi[1], Michael Kutcher[1], Renato Santos[1], Timothy Smith[1], William Little[1]
[1]Wake Forest School of Medicine, Winston-Salem, NC

Background: Recent insurance-based observational data indicate that the ratio of contrast volume (CV) use to calculated creatinine clearance predicts acute kidney injury (AKI). Whether these findings will be observed in other populations, is uncertain.

Methods: 11,986 CATH and PCI procedures were performed at a single center (Wake Forest Baptist Medical Center) between January 2007 and December 2011 and were evaluated for AKI post-procedure. A contrast minimization strategy including automated contrast injection was used in all patients. Procedures with missing pre- or post-creatinine or renal failure with dialysis were excluded (n=4,117). Glomerular filtration rate was estimated (eGFR).

Results: High risk baseline characteristics were significantly more prevalent with AKI (n=430) compared to no AKI (n=7,439), including CHF, diabetes, prior renal failure, acute MI, and elevated baseline creatinine. Per institutional standard of practice CV use was 20 mL lower per procedure for those with AKI (p<0.001), but CV/eGFR was 30% higher for those with AKI (p<0.001). After multivariable adjustment, CV/eGFR remained a significant independent predictor of AKI, with CV/eGFR ≥3.0 having 2.18 (1.59-3.00) increased odds of AKI vs. CV/eGFR <3.0 (see Figure).

Incidence of acute kidney injury by category of CV/eGFR

Conclusions: In this prospective observational registry CV/eGFR was independently predictive of AKI, with a ratio ≥3.0 associated with two-fold greater risk of AKI. These data provide strong support for the use of this metric as a risk-reduction method for AKI

POSTERS

JACC Vol 60/17/Suppl B | October 22–26, 2012 | TCT Abstracts/POSTER/Chronic Kidney Disease and Acute Renal Insufficiency

B39

following CATH and PCI, including settings in which use of contrast-sparing techniques are standard of practice.

TCT-136

Impact of pre-operative chronic kidney disease on transcatheter aortic valve implantation outcome

Nicolas Dumonteil[1], Alaide Chieffo[2], Didier Tchetche[3], Nicolas Van Mieghem[4], Bertrand Marcheix[1], Robert M A Van Der Boon[5], Gill Buchanan[6], Olivier Vahdat[3], Patrick Serruys[7], Jean Fajadet[3], Peter De Jaegere[5], Antonio Colombo[8], Didier Carrié[1]

[1]*Cardiovascular and Metabolic Pole, Rangueil Hospital, Toulouse, Toulouse, France,* [2]*San Raffael Scientific Institute, Milan, Italy, Milan, Italy,* [3]*Clinique Pasteur, Toulouse, Toulouse, France,* [4]*Erasmus MC, Rotterdam, Rotterdam, Netherlands,* [5]*Thoraxcenter, Erasmus Medical Center, Rotterdam, Rotterdam, Netherlands,* [6]*San Raffaele Scientific Institute, Milan, Italy, Milan, Italy,* [7]*Thoraxcenter, Erasmus MC, Rotterdam, Rotterdam,* [8]*EMO GVM Centro Cuore Columbus srl, Milan, Milan, Italy*

Background: There is only limited and conflicting information about the impact of pre-operative chronic kidney disease (CKD) on outcome after transcatheter aortic valve implantation (TAVI). We sought to evaluate the impact of pre-operative CKD on clinical outcome after TAVI, with either balloon- or self-expandable prosthesis, using transfemoral or alternative access, in high risk patients with severe aortic stenosis.
Methods: We retrospectively analyzed pooled data from 4 centers' prospective TAVI databases (942 patients). VARC endpoint definitions were used. Patients were subdivided into 4 categories of eGFR to examine the effect of: no (> 90 ml/min/1.73 m^2), mild (61 to 90 ml/min/1.73 m^2), moderate (31 – 60 ml/min/1.73 m^2) and severe (≤ 30 ml/min/1.73 m^2) CKD. To assess the effect of renal function on short- and long-term outcome, univariable and multivariable logistic regressions were used; no-CKD category was the reference category.
Results: No CKD was found in 109 patients (11.6%); 330 (35 %) had mild, 400 (42.4 %) moderate and 103 (11%) severe CKD. Baseline and procedural characteristics were similar among all groups except for the Logistic EuroSCORE, incidence of severe left ventricular dysfunction, anemia, and a transapical approach, which was higher when the CKD was more severe. Major stroke (severe CKD: 4.9 %, moderate: 2.8 %, mild: 1.2 %, no: 1.8 %, p=0.05), life-threatening bleeding (severe CKD: 24.3%, moderate 14.8 %, mild: 11.2 %, no: 8.3 %, p<0.001), all-cause 30-day mortality (severe CKD 9.7%, moderate 8.5%, mild 6.7%, no 1.7%, p=0.02) and one-year mortality differed significantly across CKD groups. By multivariate analysis, severe CKD (HR 4.21, 95 % CI 1.67-10.66) was an independant predictor of one-year mortality.
Conclusions: Patients with CKD who undergo TAVI have a higher risk profile and a worse 30-day and one-year outcome. Severe CKD at baseline is an independent predictor of 1-year mortality after TAVI.

TCT-137

Is Urinary Neutrophil Gelatinase-Associated Lipocalin the "Renal Troponin" in Invasive Cardiology?

Tilman Perrin[1], Eric Descombes[1], Stéphanie Gobet[1], Jean-Luc Magnin[1], Magali Gachet[1], Ould Hemett[1], Daniel Hayoz[1], Valérie Stolt[1], Gérard Baeriswyl[1], Jean-Christophe Stauffer[1], Jean-Jacques Goy[1], Mario Togni[1], Stéphane Cook[1]

[1]*Hospital and University of Fribourg, Fribourg, Switzerland*

Background: Diagnosis of acute kidney injury (AKI) relies on a late marker, namely serum creatinine (SCr). Several biomarkers are considered for an early and sensitive detection of contrast-induced nephropathy (CIN). In particular, urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) has been used for early detection of AKI in the emergency department, after cardiopulmonary bypass or following contrast medium (CM) exposition. Our study was conducted to assess the value of uNGAL as an early detector of CIN in patients undergoing percutaneous coronary procedures (PCP) and whether or not uNGAL correlates with the volume of CM.
Methods: We enrolled 244 consecutive patients undergoing PCP with Iomeprolum at our institution. CIN was defined as a ≥25% increase in SCr from baseline when measured 2-4 days after PCP. uNGAL was measured at its peak (4-6 hours after PCP) with the Abbott ARCHITECT assay.
Results: Among the patients (median[iqr] age 66.6[59.5-74.7] years, 70% male), 149(61%) underwent a diagnostic PCP and 95(39%) underwent a therapeutic PCP with a median CM volume of 123[88-168] ml. 25(10%) patients developed CIN after PCP. We found neither a significant difference in uNGAL levels between patients with and without CIN (p=0.20), nor a significant correlation between the CM volume versus uNGAL levels (r=-0.11) (Fig. 1).


Fig. 1 Perrin et al.

Conclusions: In a large cohort of patients at low-risk for contrast-induced nephropathy, urinary NGAL measured 4 to 6 hours after PCP was not useful in predicting the development of contrast-induced nephropathy and did not correlate with the volume of contrast medium used during the procedure.

TCT-138

Veropaque, A Novel Contrast Formulation, Mitigates Contrast Induced Acute Kidney Injury

Sangita Biswas[1], Elizabeth Rowe[2], Gerold Mosher[2], Lovella Insisienmay[1], Marlies Ozias[1], Michael Gralinski[3], Vernon Rowe[2]

[1]*MidAmerica Neuroscience Research Foundation, Lenexa, KS,* [2]*Verrow Pharmaceuticals, Inc, Lenexa, KS,* [3]*CorDynamics, Inc, Chicago, IL*

Background: Contrast-induced acute kidney injury (CI-AKI) continues to be an important complication of contrast administration. We've recently discovered the utility of substituted cyclodextrins (SCD) for mitigating the renal toxicity of several classes of nephrotoxic agents including antibiotics, anticancer agents and contrast agents (CA). This discovery is the basis for the development of Veropaque, a new contrast agent containing iohexol and a SCD. Here we report on preclinical animal studies using several CAs and SCDs.
Methods: Formulations containing iopamidol, iodixanol and iohexol were prepared w/wo various amounts of sulfobutylether-β-cyclodextrin (SBECD) or 2-hydroxypropyl-β-cyclodextrin (HPCD). The formulations were dosed iv at 1.5 g Iodine/kg to renally compromised (RC) mice and rats. Plasma samples were taken for creatinine analysis, and kidney pathology was evaluated at 24 or 48h. A 14-day survival study in RC rats was also conducted with 2.5g I/mL iv doses of iohexol or iohexol+SBECD (Veropaque). The iohexol and Veropaque formulations were also rapidly injected into the left main coronary artery of anesthetized instrumented dogs. ECG and hemodynamics were monitored.
Results: Small amounts of SCD added to CA formulations dramatically reduced the kidney pathology in both rats and mice at 24 and 48h and preserved kidney function as measured by plasma creatinine. The nephroprotection was observed for both SCDs and all three CAs and was dose dependent on the SCD from CA:SCD mole ratios of 1:0.0125 to 1:0.05. The SCD also reduced mortality in the 14-day study (8/8 control, 4/8 iohexol, 7/8 Veropaque survived). Intracoronary injections in the dog model revealed no significant differences between iohexol and Veropaque and no notable effects on most measured cardiovascular parameters other than transient changes in LV contractility and QTc interval as previously described in the literature.
Conclusions: SCDs are nephroprotective against CI-AKI pathology, functional changes, and mortality in rodent models without altering the expected cardiac hemodynamic and electrophysiologic effects of the CAs. Further development of Veropaque is warranted and underway.

TCT-139

Prognosis and Incidence of Acute kidney Injury According to the Valve Academic Research Consortium after Transcatheter Aortic Valve Implantation.

marc bedossa[1], vincent auffret[1], dominique boulmier[1], erwan donal[1], jean philippe Verhoye[2], gienvitto ruggieri[1], herve le breton[1]

[1]*department of cardiology, Rennes, France,* [2]*department of cardiac surgery, Rennes, France*

Background: Few data are currently available about the characteristics and procedural features associated with Acute kidney Injury (AKI) after Transcatheter Aortic Valve Implantation (TAVI) using the new recommended Valve Academic Research Consortium (VARC) definition.

POSTERS